- Home
- SGHT vs NCZ Comparison
SGHT vs NCZ Comparison
Compare SGHT & NCZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGHT
- NCZ
- Stock Information
- Founded
- SGHT 2011
- NCZ 2003
- Country
- SGHT United States
- NCZ United States
- Employees
- SGHT N/A
- NCZ N/A
- Industry
- SGHT Medical Specialities
- NCZ Finance Companies
- Sector
- SGHT Health Care
- NCZ Finance
- Exchange
- SGHT Nasdaq
- NCZ Nasdaq
- Market Cap
- SGHT 193.2M
- NCZ 228.3M
- IPO Year
- SGHT 2021
- NCZ N/A
- Fundamental
- Price
- SGHT $5.24
- NCZ $13.88
- Analyst Decision
- SGHT Buy
- NCZ
- Analyst Count
- SGHT 8
- NCZ 0
- Target Price
- SGHT $4.50
- NCZ N/A
- AVG Volume (30 Days)
- SGHT 221.6K
- NCZ 533.0K
- Earning Date
- SGHT 11-06-2025
- NCZ 01-01-0001
- Dividend Yield
- SGHT N/A
- NCZ 12.16%
- EPS Growth
- SGHT N/A
- NCZ N/A
- EPS
- SGHT N/A
- NCZ N/A
- Revenue
- SGHT $76,303,000.00
- NCZ N/A
- Revenue This Year
- SGHT N/A
- NCZ N/A
- Revenue Next Year
- SGHT $12.04
- NCZ N/A
- P/E Ratio
- SGHT N/A
- NCZ N/A
- Revenue Growth
- SGHT N/A
- NCZ N/A
- 52 Week Low
- SGHT $2.03
- NCZ $2.50
- 52 Week High
- SGHT $5.52
- NCZ $3.15
- Technical
- Relative Strength Index (RSI)
- SGHT 76.45
- NCZ 51.20
- Support Level
- SGHT $3.22
- NCZ $13.45
- Resistance Level
- SGHT $5.32
- NCZ $14.02
- Average True Range (ATR)
- SGHT 0.31
- NCZ 0.30
- MACD
- SGHT 0.22
- NCZ -0.06
- Stochastic Oscillator
- SGHT 93.93
- NCZ 40.91
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
About NCZ Virtus Convertible & Income Fund II of Beneficial Interest
Virtus Convertible & Income Fund II is a diversified, closed-end management investment company. The investment objective of the company is to provide total return through a combination of capital appreciation and high current income. Its portfolio of investments includes different sector investments such as in healthcare services, media, oil, gas, and consumable fuels and others.